Biopharma has finally begun catching up with the overall stock market, if the positive returns shown by the top three exchange traded funds (ETFs) since the spring are any indication. Over the past six months, shares of the top three biopharma ETFs have jumped well into double digits. The top biotech-focused ETF with $6.562 billion…
By Andrew Silver SHANGHAI (Reuters) -Pharmaceutical research and development firms in China are increasingly interested in procuring critical supplies known as reagents from local manufacturers, industry executives and managers said, as they seek to cut costs and delivery times. Western reagent suppliers including U.S.-based Thermo Fisher Scientific and Germany’s Merck have profited in the world’s…
In This Story Shaken by geopolitical shocks, the S&P 500 was flat last week and the Nasdaq nosed just into the red — but the Dow Jones Industrial Average finished significantly lower, weighed down by a double blow from UnitedHealth (UNH) and Nvidia (NVDA). How Trump’s tariffs could make your iPhone cost $3,500 UnitedHealth slashed…
A Europe-based Huawei executive has decried policies to block the Chinese tech company’s entry into certain markets and warned that this could limit the development of the European artificial intelligence industry. Tony Jin Yong, Huawei’s vice-president for Europe, said he was puzzled by measures to form “exclusive groups” among “like-minded countries”, though he did not…